Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9765684 | 0.91 | L3MBTL1 (0.55) | L3MBTL1PARP1MTNR1AMTNR1BAOC3 | |
| SCHEMBL7743641 | 0.87 | MTNR1A (0.52) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL11215919 | 0.85 | PTGS1 (0.50) | L3MBTL1TRPM8PTGS1 | |
| SCHEMBL8534165 | 0.85 | L3MBTL1 (0.50) | L3MBTL1PARP1MTNR1AMTNR1BAOC3 | |
| SCHEMBL18978189 | 0.85 | L3MBTL1 (0.50) | L3MBTL1PARP1MTNR1AMTNR1BAOC3 | |
| SCHEMBL18978188 | 0.83 | L3MBTL1 (0.48) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL10382783 | 0.83 | L3MBTL1 (0.48) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL25226434 | 0.81 | L3MBTL1 (0.65) | L3MBTL1TRPM8PARP1AOC3PTGS1 | |
| SCHEMBL11483148 | 0.81 | L3MBTL1 (0.65) | L3MBTL1TRPM8PARP1AOC3PTGS1 | |
| SCHEMBL9457197 | 0.81 | L3MBTL1 (0.56) | L3MBTL1TRPM8PARP1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | L3MBTL1 4865/4885TRPM8 4228/4885PARP1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.